Seven Eight Capital, LP Acadia Pharmaceuticals Inc Transaction History

Seven Eight Capital, LP

$1.05 Billion
Q3 2024

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$17.79 - $30.86 $1.51 Million - $2.62 Million	84,964 Added 128.33%	151,171 $2.8 Million
Q4 2023 Feb 13, 2024	BUY	$20.78 - $31.77 $185,108 - $283,007	8,908 Added 15.55%	66,207 $2.07 Million
Q3 2023 Nov 14, 2023	BUY	$20.84 - $33.47 $74,503 - $119,655	3,575 Added 6.65%	57,299 $1.19 Million
Q2 2023 Aug 14, 2023	BUY	$17.8 - $25.65 $956,287 - $1.38 Million	53,724 New	53,724 $1.29 Million
Q3 2022 Nov 10, 2022	BUY	$14.11 - $18.27 $380,052 - $492,102	26,935 New	26,935 $441,000
Q2 2022 Aug 04, 2022	SELL	$13.01 - $27.22 $142,108 - $297,324	-10,923 Closed	0 $0
Q1 2022 May 11, 2022	BUY	$20.94 - $27.5 $228,727 - $300,382	10,923 New	10,923 $265,000
Q4 2020 Feb 09, 2021	SELL	$41.04 - $56.79 $215,788 - $298,601	-5,258 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$36.42 - $57.0 $171,538 - $268,470	-4,710 Reduced 47.25%	5,258 $217,000
Q2 2020 Aug 06, 2020	BUY	$39.26 - $52.73 $391,343 - $525,612	9,968 New	9,968 $483,000
Q1 2020 May 14, 2020	SELL	$31.65 - $46.87 $2.95 Million - $4.36 Million	-93,099 Closed	0 $0
Q4 2019 Feb 13, 2020	SELL	$36.21 - $51.4 $1.61 Million - $2.28 Million	-44,370 Reduced 32.28%	93,099 $3.98 Million
Q3 2019 Nov 14, 2019	BUY	$22.22 - $44.01 $2.43 Million - $4.81 Million	109,225 Added 386.72%	137,469 $4.95 Million
Q2 2019 Aug 12, 2019	BUY	$23.32 - $28.12 $473,396 - $570,836	20,300 Added 255.54%	28,244 $755,000
Q1 2019 May 15, 2019	BUY	$16.17 - $27.38 $128,454 - $217,506	7,944 New	7,944 $213,000
Q4 2017 Feb 12, 2018	SELL	$26.84 - $39.14 $950,216 - $1.39 Million	-35,403 Closed	0 $0
Q3 2017 Oct 16, 2017	BUY	$29.49 - $38.37 $1.04 Million - $1.36 Million	35,403	35,403 $1.33 Million

Others Institutions Holding ACAD

# of Institutions

279

Shares Held

156M

Call Options Held

901K

Put Options Held

314K

View Full List

About ACADIA PHARMACEUTICALS INC

Ticker ACAD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 161,843,008
Market Cap $2.76B
Description
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...

More about ACAD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Seven Eight Capital, LP, based on Form 13F filings with the SEC.

News

Stay updated on Seven Eight Capital, LP with notifications on news.

Account